sr141716 has been researched along with Huntington Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dragunow, M; Glass, M; Goodfellow, CE; Graham, ES; Scotter, EL | 1 |
| de Miguel, R; De Petrocellis, L; Di Marzo, V; Fernández-Ruiz, J; Lastres-Becker, I; Makriyannis, A | 1 |
| Bizat, N; Boyer, F; Brouillet, E; Fernández-Ruiz, J; Hantraye, P; Lastres-Becker, I | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Maccarrone, M; Prosperetti, C; Rossi, S; Tscherter, A | 1 |
4 other study(ies) available for sr141716 and Huntington Disease
| Article | Year |
|---|---|
Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
Topics: Animals; Butadienes; Cell Culture Techniques; Cell Death; Cell Line, Transformed; Cerebellum; Cyclic AMP; Dronabinol; GTP-Binding Protein alpha Subunits; Humans; Huntingtin Protein; Huntington Disease; Mice; Mitogen-Activated Protein Kinase 3; Nerve Tissue Proteins; Neuroprotective Agents; Nitriles; Nuclear Proteins; PC12 Cells; Pertussis Toxin; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Rimonabant | 2010 |
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Cannabinoid Receptor Modulators; Capsaicin; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Dopamine; Endocannabinoids; gamma-Aminobutyric Acid; Huntington Disease; Hyperkinesis; Male; Motor Activity; Nitro Compounds; Palmitates; Piperidines; Propionates; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |
Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
Topics: Animals; Cannabinoid Receptor Modulators; Cannabinoids; Corpus Striatum; Disease Models, Animal; Dronabinol; Electron Transport Complex II; Enzyme Inhibitors; Huntington Disease; Male; Malonates; Multienzyme Complexes; Oxidoreductases; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Succinate Dehydrogenase | 2003 |
Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.
Topics: Animals; Animals, Newborn; Cannabinoid Receptor Antagonists; Corpus Striatum; Drug Interactions; Electric Stimulation; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Huntington Disease; In Vitro Techniques; Membrane Potentials; Mice; Mice, Transgenic; Neural Inhibition; Neurons; Patch-Clamp Techniques; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Synaptic Transmission; Time Factors | 2005 |